Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends<\/p>\n
The leading gene-editing companies looking at commercializing CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. CRISPR Therapeutics has the largest market cap of the three, at $10.9B, with a clinical development program that is more advanced than those of Intellia and Editas. Editas Medicine has the smallest market cap of the three companies. Intellia has established high profile collaborations with Regeneron and Novartis.<\/p>\n
DelveInsights CRISPR Therapies Pipeline Insight report offers a broad view of available CRISPR therapies in the market, pipeline CRISPR therapies, their MoA, RoA, key companies working in the domain and competitive assessment. <\/p>\n
Some of the key takeaways from the CRISPR Therapies Pipeline Report:<\/p>\n
Interested in knowing more? Request for the sample @ CRISPR Therapies in the Pipeline<\/p>\n
The report underlines the present unmet needs in the market, driving factors and market constraints, along with the holistic view of the inactive therapeutics (comprising dormant and terminated products) with the reasons behind their downfall, detailed insights into the structure and gene editing tool of the pipeline CRISPR therapies to help clients gauge the opportunities and risks in the market.<\/p>\n
In the News<\/p>\n
Know what is happening in the CRISPR Pipeline Therapies @ CRISPR Pipeline Recent Happenings<\/p>\n
What is CRISPR?<\/p>\n
CRISPRs (Clusters of Regularly Interspaced Short Palindromic Repeats) are specialized stretches of DNA and are a shorthand for CRISPR-Cas9, which are transcribed by the bacteria to RNA stretches during viral infections. The same CRISPR technology can be leveraged to identify, alter and modify the DNA sequences and genomes. <\/p>\n
The technique is used to correct genetic defects, prevent the spread of disease by altering the genetic sequence, improving crop viability and durability, and so on without affecting the functions of other genes. <\/p>\n
Want to learn more about the leading candidates in different clinical stages of trials? Reach out @ CRISPR Emerging Therapies and Key Companies<\/p>\n
At a Glance: Emerging CRISPR Therapies, RoA, MoA and Companies<\/p>\n
Know more about budding CRISPR therapies projected to transform the landscape @ Emerging CRISPR Therapeutics and Market Scenario<\/p>\n
CRISPR Therapeutic Assessment The CRISPR Therapies Pipeline report proffers comprehensive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target and Indications of various drugs.<\/p>\n
By Product Type<\/p>\n
By Stage<\/p>\n
By Route of Administration<\/p>\n
By Mechanism of Action<\/p>\n
By Targets<\/p>\n
By Stage and Route of Administration<\/p>\n
By Stage and Product Type<\/p>\n
To know more, Visit CRISPR CAS-9 Technology and Emerging Trends<\/p>\n
Scope of the report <\/p>\n
Learn more about the scope and highlights of the report @ CRISPR Pipeline Emerging Drug Pipeline<\/p>\n
Key Questions Answered in the Report<\/p>\n
Got queries? Get in touch @ CRISPR Technology and Pipeline Therapies<\/p>\n
Table of Contents <\/p>\n
Know more about report offerings @ CRISPR Pipeline Insights <\/p>\n
Related Reports Adeno Associated Virus Vectors In Gene Therapy MarketDelveInsight's \"Adeno-Associated Virus Vectors in Gene Therapy - Market Insights, Epidemiology, and Market Forecast-2030\" report.<\/p>\n
Gene Therapy In Oncology Innovation To Commercialization Competitive LandscapeDelveInsights Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions, 2018 report.<\/p>\n
Complicated Urinary Tract Infections MarketDelveInsight's \"Complicated Urinary Tract Infections - Market Insights, Epidemiology, and Market Forecast-2030\" report.<\/p>\n
Usher Syndrome Type 2 MarketDelveInsight's \"Usher Syndrome Type 2 - Market Insights, Epidemiology, and Market Forecast-2030\" report.<\/p>\n
Diffuse Large B Cell Lymphoma MarketDelveInsight's \"Diffuse Large B-cell Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030\" report.<\/p>\n
Beta Thalassemia Thal MarketDelveInsight's \"Beta-thalassemia (B-thal) - Market Insights, Epidemiology, and Market Forecast-2030\" report.<\/p>\n
Sickle Cell Disease MarketDelveInsight's \"Sickle Cell Disease - Market Insights, Epidemiology, and Market Forecast-2030\" report.<\/p>\n
Gene and Cell Therapies in CNS DisordersAnalysis of the key companies in the domain is BrainStorm Cell Therapeutics, Helixmith, Q therapeutics, Neuroplast, StemCyte, Axovant, Libella Gene Therapeutics, Voyager Therapeutics and many others. <\/p>\n
CRISPR Gene-Editing and Stem-Cell Technology<\/p>\n
About DelveInsight<\/p>\n
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.<\/p>\n
<\/p>\n
See the original post here: Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends The leading gene-editing companies looking at commercializing CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. CRISPR Therapeutics has the largest market cap of the three, at $10.9B, with a clinical development program that is more advanced than those of Intellia and Editas. Editas Medicine has the smallest market cap of the three companies. Continue reading
\nCRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"